IMMUNOTHERAPY VERSUS PHARMACOTHERAPY AMONG PATIENTS WITH ALLERGIC RHINITIS BASED ON TOTAL SYMPTOM SCORE AND MEDICATION SCORE.-Reference-Cited by-同舟云学术

IMMUNOTHERAPY VERSUS PHARMACOTHERAPY AMONG PATIENTS WITH ALLERGIC RHINITIS BASED ON TOTAL SYMPTOM SCORE AND MEDICATION SCORE.

Published:2021-02-01 Issue: Volume: Page:78-80
ISSN:
Container-title:INDIAN JOURNAL OF APPLIED RESEARCH
language:en
Short-container-title:IJAR

Author:

K Arun Govind¹,Mohindra Satyawati²,Gupta Ashok K.³,Mahendru Shaurya⁴

Affiliation:

1. MS. Senior Resident, Department of Otolaryngology, Head and Neck Surgery, Pgimer, Chandigarh, India.

2. MS, DNB Professor., Department of Otolaryngology, Head and Neck Surgery, Pgimer, Chandigarh, India

3. Ex-Professor., Department of Otolaryngology, Head and Neck Surgery, Pgimer, Chandigarh, India.

4. Undergraduate, Dayanad Medical College, Ludhiana, India.

Abstract

Objective: To compare efcacy of immunotherapy and pharmacotherapy in patients with allergic rhinitis using total symptom score and rescue medication score. Prospective analysis of outcomes Design: of different treatment modalities in allergic rhinitis patients in a tertiary care centre. Hundred and ten pa Subjects: tients, diagnosed to have allergic rhinitis were included in this study, they were divided into 2 groups based on treatment modality i:e, pharmacotherapy (Group A) and immunotherapy group (Group B). Former contained 76 patients and latter 34 patients The pretreatment mean t Results: otal symptom score (TSS) in pharmacotherapy group was 7.76±3.8 and in immunotherapy group 10.88±2.45. Post treatment mean total symptom score was 7.31±3.68 and 6.29±3.01 respectively. Mean rescue medication score (RMS) in pharmacotherapy group was 0.40±0.22 and immunotherapy was 0.28±0.18. Conclusion: Both pharmacotherapy and immunotherapy was efcacious and safe in treating patients with AR , but the magnitude of reduction was more in immunotherapy group. Regardless of the sensitisation status of the patients (even if the patient is polysensitised ) they responded well with single allergen immunotherapy. Reduction in rescue medication score was statistically signicant in those receiving immunotherapy giving a stable control. Immunotherapy can also be used as anti symptomatic treatment and has the capacity to modify the course of illness

Publisher

World Wide Journals

Reference14 articles.

1. Shah A, Pawankar R. Allergic Rhinitis and Co-morbid Asthma: Perspective from India- ARIA Asia- Pacific Workshop Report. Allerg rhinitis.2009;27:71-77.

2. Zuberbier T, Lötvall J, Simoens S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the European Union: a GA 2 LEN review. Allergy. 2014 ;69:1275–9.

3. Craig TJ, King TS, Lemanske RF, Wechsler ME, Icitovic N, Zimmerman RR, et al. Aeroallergen sensitization correlates with PC20 and exhaled nitric oxide in subjects with mild-to-moderate asthma. J Allergy Clin Immunol. 2008;121:671–7.

4. Langen U. Asthma and Sensitization Pattern in Children. In: Pereira C, editor. Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment.2012

5. Didier A, Chartier A, Démonet G. Immunothérapie sublinguale : pour quel profil de patients en pratique ? Analyse intermédiaire d’Odissee (observatoire de l’indication, du choix de prise en charge par immunothérapie spécifique sublinguale ainsi que de l’adhésion et de l’observance au traitement chez les patients souffrant d’allergie respiratoire [rhinite et/ou conjonctivite et/ou asthme allergique]). Rev Fr Allergol. 2010 ;50:426–33.